CN109415698A - 工程化Treg细胞 - Google Patents

工程化Treg细胞 Download PDF

Info

Publication number
CN109415698A
CN109415698A CN201780037655.8A CN201780037655A CN109415698A CN 109415698 A CN109415698 A CN 109415698A CN 201780037655 A CN201780037655 A CN 201780037655A CN 109415698 A CN109415698 A CN 109415698A
Authority
CN
China
Prior art keywords
cell
regulatory
treg
foxp3
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780037655.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·Y·鲁坚斯基
T·知念
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Si Long-Kate Woods Is Commemorated Cancer Center
Original Assignee
Si Long-Kate Woods Is Commemorated Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Si Long-Kate Woods Is Commemorated Cancer Center filed Critical Si Long-Kate Woods Is Commemorated Cancer Center
Publication of CN109415698A publication Critical patent/CN109415698A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
CN201780037655.8A 2016-06-16 2017-06-15 工程化Treg细胞 Pending CN109415698A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351104P 2016-06-16 2016-06-16
US62/351,104 2016-06-16
PCT/US2017/037794 WO2017218850A1 (en) 2016-06-16 2017-06-15 Engineered treg cells

Publications (1)

Publication Number Publication Date
CN109415698A true CN109415698A (zh) 2019-03-01

Family

ID=60663377

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780037655.8A Pending CN109415698A (zh) 2016-06-16 2017-06-15 工程化Treg细胞

Country Status (8)

Country Link
US (1) US20190322983A1 (https=)
EP (1) EP3472305A4 (https=)
JP (2) JP2019518460A (https=)
CN (1) CN109415698A (https=)
AU (1) AU2017285319A1 (https=)
CA (1) CA3027546A1 (https=)
MA (1) MA45498A (https=)
WO (1) WO2017218850A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115427440A (zh) * 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098202B2 (en) * 2016-10-10 2024-09-24 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
US20210017248A1 (en) * 2018-03-16 2021-01-21 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
EP3820509A1 (en) 2018-07-09 2021-05-19 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
KR20210125509A (ko) * 2019-02-01 2021-10-18 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
CA3146013A1 (en) 2019-07-09 2021-01-14 The Children's Mercy Hospital Engineered regulatory t cells
WO2021154882A1 (en) * 2020-01-27 2021-08-05 H. Lee Moffitt Cancer Center And Research Institute Inc. Hdac6-inhibited human regulatory t cells
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
KR20250169635A (ko) 2023-01-23 2025-12-03 메디치니쉐 호흐슐레 하노버 항-entpd3 키메라 항원 수용체
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
IL322333A (en) 2023-02-07 2025-09-01 Quell Therapeutics Ltd Culture method for TREG cells
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4669343A1 (en) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover CHIMERIC ANTIGEN RECIPIENT
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes
EP2167647A2 (en) * 2007-06-13 2010-03-31 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
ES2928000T3 (es) * 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
AU2015276131A1 (en) * 2014-06-17 2016-11-17 Cellectis CD123 specific multi-chain chimeric antigen receptor
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. VOGTENHUBER ET AL,: "Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses", 《BLOOD》 *
JETHWA HANNAH ET AL: "Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: Is now the right time?", 《CLINICAL IMMUNOLOGY》 *
MATTHEW A. BURCHILL ET AL,: "Distinct Effects of STAT5 Activation on CD4 + and CD8 + T Cell Homeostasis: Development of CD4 + CD25 + Regulatory T Cells versus CD8 + Memory T Cells", 《 THE JOURNAL OF IMMUNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115427440A (zh) * 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体

Also Published As

Publication number Publication date
JP2022058995A (ja) 2022-04-12
AU2017285319A1 (en) 2018-12-20
EP3472305A1 (en) 2019-04-24
JP2019518460A (ja) 2019-07-04
WO2017218850A1 (en) 2017-12-21
MA45498A (fr) 2019-04-24
CA3027546A1 (en) 2017-12-21
EP3472305A4 (en) 2020-01-15
US20190322983A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
CN109415698A (zh) 工程化Treg细胞
Li et al. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death
Bod et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity
Fujikado et al. Aire inhibits the generation of a perinatal population of interleukin-17A-producing γδ T cells to promote immunologic tolerance
Mathä et al. Migration of lung resident group 2 innate lymphoid cells link allergic lung inflammation and liver immunity
Solé et al. AT follicular helper cell origin for T regulatory type 1 cells
Umeshappa et al. Re-programming mouse liver-resident invariant natural killer T cells for suppressing hepatic and diabetogenic autoimmunity
US20220386573A1 (en) Humanized mouse model with human immune system
Shao et al. Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation
WO2025030118A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
Murphy et al. Overcome prostate cancer resistance to immune checkpoint therapy with ketogenic diet-induced epigenetic reprogramming
Castiello et al. HyperIgE in hypomorphic recombination-activating gene defects
Budeus et al. Human neonatal B cell immunity differs from the adult version by conserved Ig repertoires and rapid, but transient response dynamics
Raghavan et al. Conditional deletion of Pdcd1 identifies the cell-intrinsic action of PD-1 on functional CD8 T cell subsets for antitumor efficacy
Nater et al. Hepatic iNKT cells facilitate colorectal cancer metastasis by inducing a fibrotic niche in the liver
US20190376030A1 (en) Regulatory t cell populations
Xia The Maintenance of CD4 and CD8 T Cell Response to Persistent Antigens
Habrylo The Decoy Receptor IL-1R2 Attenuates Treg Activation in Tumors
US20260097078A1 (en) Regulation of cells and organisms
Orangi The role of innate lymphoid cells in steatohepatitis and liver fibrosis
Fonseca Modulation of Intestinal Networks by Neutrophils and Group 3 Innate Lymphoid Cells
Deep Regulation of Polytypic T Cell Responses in Infection
Westermann A Non-Classical Ontogenetic Path Gives Rise to a GM-CSF Dependent Macrophage Population in the Developing Salivary Gland
Anstee Macrophage development in the perivascular niche and their role in cancer progression
Liu et al. The transcription factor EHF promotes the maturation and immunosuppression of conventional dendritic cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301